Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report

BMC Ophthalmology, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 23, 2025

To report a case of intraocular inflammation (IOI) after intravitreal injection aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration. An 80-year-old man with diabetes mellitus had degeneration refractory to treatment 2 mg. Despite ten injections faricimab, the exudation remained, and we switched brolucizumab, which resulted in mild IOI. The IOI improved only topical steroids, back exudation. However, decided switch careful discussion patient. Two weeks later, he experienced minor ocular pain photophobia. One month although dry macula was achieved, severe visual impairment occurred due anterior chamber inflammation, retinal vasculitis, vascular occlusion. We diagnosed following immediately started steroid eye drops sub-Tenon triamcinolone acetonide. Although resolved, his acuity did not improve. This demonstrated potential dose-dependent inflammatory response mg, occur patients history inflammation.

Language: Английский

---

Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series

BMC Ophthalmology, Journal Year: 2024, Volume and Issue: 24(1)

Published: Dec. 2, 2024

Monitoring for potential inflammatory events following intravitreal anti-vascular endothelial factor (VEGF) injection is crucial with the use of new agents such as aflibercept 8 mg. Despite a safety profile comparable to 2 mg in pivotal and phase 3 studies, reporting cases clinical practice helps evaluate risk these agents. In this case series, cluster patients manifesting acute intraocular inflammation (IOI) after at three different centers are described. All developed vitreous anterior chamber within 2–17 days injection. subjects had previously received growth therapy (ranibizumab, or faricimab) without injection-related complications. No signs vasculitis, papillitis retinitis were noted. view presentation, cultures not performed. Inflammation resolved topical steroids non-steroidal anti-inflammatory drugs over course 11–24 excellent visual recovery. We report ocular present unknown cause. It underlines need awareness detect despite low-risk studies.

Language: Английский

---

Increased Risk of Retinal Vasculitis May Be Associated with Aflibercept 8 mg: A Pharmacovigilance Analysis of the FAERS Database

Ocular Immunology and Inflammation, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 3

Published: March 6, 2025

To evaluate the risk of retinal vasculitis and related adverse events (AEs) among five commercially available anti-vascular endothelial growth factor (anti-VEGF) agents using data from FDA Adverse Event Reporting System (FAERS). A retrospective pharmacovigilance study was conducted FAERS Q1 2004 to Q4 2024. drug reactions (ADRs) were categorized Medical Dictionary for Regulatory Activities (MedDRA), with "Retinal Vasculitis" as primary outcome "Uveitis" "Vitritis" secondary outcomes. Disproportionality analysis performed ranibizumab reference drug. Logistic regression identified associations between demographic factors ADRs. The included only reports linking a single ADR limited patients aged ≥18 years. Out 49,114 initial 45,768 met inclusion criteria. Retinal reported in 314 cases (0.7%), vitritis 689 (1.5%), uveitis 1,344 (2.9%). Older age (OR 1.012; p = 0.045) female sex 1.747; < 0.001) significantly associated vasculitis. All showed higher odds compared ranibizumab, brolucizumab having highest reporting ratio (ROR) (331.61). Aflibercept 8 mg ROR (62.8) 2 dose (3.82). This safety signal indicating possible increased aflibercept conventional dose. finding requires confirmation through future postmarketing studies.

Language: Английский

---

Advancements in age-related macular degeneration treatment: From traditional anti-VEGF to emerging therapies in gene, stem cell, and nanotechnology

Biochemical Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 116902 - 116902

Published: March 1, 2025

Language: Английский

---

Early real-world outcomes of intravitreal aflibercept 8 mg in treatment-Naïve neovascular AMD: AI-assisted fluid volume analysis

International Journal of Retina and Vitreous, Journal Year: 2025, Volume and Issue: 11(1)

Published: April 8, 2025

Abstract Background This study was conducted as a retrospective, exploratory analysis to assess early anatomical and functional effects of intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (nAMD) small cohort patients. Methods retrospective at the Jules Gonin Eye Hospital Lausanne, Switzerland, included treatment-naïve patients with nAMD. Patients received minimum two injections (IVT) over 3-month period. Key outcomes assessed were changes best-corrected visual acuity (BCVA), central subfield thickness (CST), mean retinal (RT), total fluid (TF) volume which calculated sum intraretinal (IRF), subretinal (SRF) pigment epithelial detachment (PED) volumes. These parameters evaluated baseline, month 1, 3 using RetinAI Discovery ® platform, an artificial intelligence-based system. Results 10 eyes enrolled. Mean age 77.7 ± 12.5 years. Comparative between revealed statistically significant reduction CST, RT TF volume, indicating positive response treatment. One adverse event intraocular inflammation (IOI) occurred one patient (10%) after second IVT injection. Treatment subsequently interrupted, IOI resolved topical corticosteroids therapy. Conclusion Intravitreal demonstrated improvements nAMD first 3-months. The use AI-based allowed for detailed automated assessment changes, providing valuable insights into treatment effects. Given design cohort, further studies are warranted long-term potential predictive value on prognosis safety. Clinical trial number Not applicable.

Language: Английский

---

Noninfectious Intraocular Inflammation After Intravitreal Aflibercept

JAMA Ophthalmology, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Aflibercept, 8 mg, is an anti-vascular endothelial growth factor (VEGF) formulation for neovascular age-related macular degeneration (nAMD) and diabetic edema (DME). While clinical trials report a comparable safety profile as aflibercept, 2 practice setting (so-called real-world) data on the incidence of intraocular inflammation (IOI) should be value. To determine IOI after intravitreal injection nAMD DME. This retrospective case series involved review medical records at single tertiary care center. Participants were all patients who received or DME from March 2024 to October 2024. Patients had injections with other VEGF inhibitors before. Standard included slitlamp examination before each follow-up within 4 days every injection. adverse events (AEs) injections. Incidence mg. Secondary outcomes time point best-corrected visual acuity (BCVA) during recovery IOI. Forty-one treated injections: 23 (56%) 18 (44%). Twenty-seven (66%) male 14 female (34%). A total 136 administered observation period. Five 41 developed mild sterile 1 3 intervention (incidence per injection, 3.7%; 95% CI, 1.6%-8.3%; patient, 12%; 5.3%-25.5%). Four prior exposure occurred; only patient first dose. All local anti-inflammatory therapy (topical subconjunctival corticosteroids), additional systemic oral corticosteroids. No reduction BCVA was observed IOI-associated AEs receded. analysis in revealed more frequent occurrence compared previous trials. cases showed IOI, which resolved under without loss BCVA.

Language: Английский

---

Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 26, 2024

Background To report a case of intraocular inflammation (IOI) after intravitreal injection aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration.Case presentation An 80-year-old man with diabetes mellitus had degeneration refractory to treatment 2 mg. Despite ten injections faricimab, the exudation remained, and we switched brolucizumab, which resulted in mild IOI. The IOI improved only topical steroids, back exudation. However, decided switch careful discussion patient. Two weeks later, he experienced minor ocular pain photophobia. One month although dry macula was achieved, severe visual impairment occurred due anterior chamber inflammation, retinal vasculitis, vascular occlusion. We diagnosed following immediately started steroid eye drops sub-Tenon triamcinolone acetonide. Although resolved, his acuity did not improve.Conclusions This demonstrated potential dose-dependent inflammatory response mg, occur patients history inflammation.

Language: Английский

---

Immunogenicity in intravitreal anti-VEGF therapy: a call for balance and maturity in evaluating safety profiles

International Ophthalmology, Journal Year: 2024, Volume and Issue: 44(1)

Published: Dec. 5, 2024

Language: Английский

---